Pluvia Biotech appoints Willem van Weperen as new CEO
Pluvia Biotech announces the appointment of Willem van Weperen as its new Chief Executive Officer (CEO).
Willem van Weperen comes to the company with an extensive background in rare disease development and commercialization. In his early career this included several roles in Genzyme, where the rare disease business model was pioneered. Subsequently, Willem was several years CEO of early-stage CNS company to-BBB, which was followed by senior commercial leadership roles at rare disease companies Prosensa, Amicus (a leader in pharmacological chaperone therapy), Myokardia and most recently Intercept. Willem holds a MSc in Biomedical Sciences from Utrecht University and an MBA from Bradford University.
Read more here: https://pluviabiotech.com/wp-content/uploads/2023/10/Press-release-Pluvia-progress-CEO-4Oct2023.pdf